Cargando…
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores
Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long‐term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase–to–platelet ratio ind...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701463/ https://www.ncbi.nlm.nih.gov/pubmed/36221305 http://dx.doi.org/10.1002/hep4.2098 |